Pro News Exclusive
What to know about looming FDA decision on first gene-editing therapy
The deadline approaches for the FDA to make a call on the first gene therapy that modifies the stem cells of people with severe sickle cell disease, after U.K. regulators approved the drug, called Casgevy, made by Vertex and CRISPR Therapeutics. Fill out the form to read the full article.
Fill out the form to read the full article.